Vaccination against COVID-19 in Individuals with Mental Illness
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1990
Special Issue Editors
Interests: substance disorders; depression; dementia; mental illness
Interests: addiction; child and adolescent mental health; psychiatry; sex research; sexual minority
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Vaccination is one of the most cost-effective ways of avoiding contracting coronavirus disease 2019 (COVID-19). However, several issues regarding vaccination against COVID-19 among the individuals with mental illness warrants study. For, example, the individuals with severe mental illness have a lower rate of COVID-19 vaccine uptake compared with the general population. Caregivers of children with neurodevelopmental disorders may worry about the effects of vaccines against COVID-19. The predictors of vaccine uptake and programs to enhance the motivation and behavior of vaccine uptake among these groups warrant further exploration. The possible interaction between COVID-19 vaccines and psychopharmacological treatment and psychological symptoms are also not clear. This issue is open to the submission of studies investigating vaccination against COVID-19 among the individuals with various mental illnesses. The studies on this issue can provide knowledge to diminish the unknown in the effects of vaccination against COVID-19 among the individuals with mental illness.
Dr. Peng-Wei Wang
Prof. Dr. Cheng-Fang Yen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine for COVID-19
- mental illness
- drug interaction
- adverse effects of vaccines
- psychopharmacological treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.